> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves Yuvezzi Combination Eye Drop for Presbyopia
- URL: https://www.fdaweb.com/fda-approves-yuvezzi-combination-eye-drop-for-presbyopia/
- Published: 2026-01-29T12:00:00.000Z
- Updated: 2026-09-14T15:32:01.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160565

FDA has approved Tenpoint Therapeutics’ Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% (previously known as Brimochol PF) as the only dual-agent eye drop to treat presbyopia in adults. A company [statement](https://tenpointtherapeutics.com/wp-content/uploads/2026/01/Tenpoint-Therapeutics-Receives-US-FDA-Approval-YUVEZZI%5FFinal%5F1%5F28%5F26.pdf?ref=fdaweb.com) says the approval was based on positive data from two Phase 3 studies enrolling over 800 patients that demonstrated a superior benefit for the combination therapy over either of the two individual active ingredients.

The most common Yuvezzi side effects are reported to be headache, impaired vision, and temporary eye pain or eye irritation.

Tenpoint says the proposed mechanism of action for Yuvezzi in presbyopia is pupillary constriction and the creation of a pinhole effect that improves near visual acuity and depth of focus.